The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
Catalyst Pharmaceuticals (Nasdaq: CPRX) and The University of Notre Dame announced the inaugural Catalyst Advocacy Scholars Summit (CASS), a week-long immersive program for 12 students enrolled in Notre Dame’s Patient Advocacy Minor.
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) and The University of Notre Dame announced the inaugural Catalyst Advocacy Scholars Summit (CASS), a week-long immersive program for 12 students enrolled in Notre Dame’s Patient Advocacy Minor.
The summit runs January 5–9, 2026 in Coral Gables, Fla., and is designed to educate students on patient advocacy and biopharmaceutical operations while giving Catalyst access to student perspectives on its programs. Catalyst said it aims to attract talent to the industry and increase patient focus across scientific degree programs.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CPRX
In the Jan 5 session, CPRX declined 1.51%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Program duration
- 1 week
- Biopharmaceutical learning intensive duration
- Student participants
- 12 students
- Number of Notre Dame students selected for CASS
- Summit dates
- January 5–9, 2026
- Dates of inaugural Catalyst Advocacy Scholars Summit
Historical Context
-
Announced presentation at J.P. Morgan Healthcare Conference with webcast access.
-
Management participation in Bank of America CNS Therapeutics Virtual Conference.
-
Ranked on Deloitte Technology Fast 500™ based on 249% revenue growth.
-
Planned presentation at Citi’s 2025 Global Healthcare Conference with webcast.
-
Reported Q3 2025 revenue growth, raised guidance, and announced share repurchase.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biopharmaceutical medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive
CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced their inaugural Catalyst Advocacy Scholars Summit (CASS). This one-of-a-kind program was created with The University of Notre Dame’s Patient Advocacy Minor Department to provide participating students with an immersive learning experience exploring the opportunities and challenges of delivering medicine to people living with rare diseases.
“We at Catalyst are excited about this unique program that we hope will help attract the best minds to the biopharmaceutical industry and increase patient focus across scientific degree programs,” said Rich Daly, President and CEO, Catalyst. “We look forward to welcoming 12 inspiring students selected by the university to spend time with Catalyst colleagues to get to know the people and functions that make our organization successful. In addition to the students learning about the incredible work involved in Patient Advocacy and navigating the biopharmaceutical industry, Catalyst will benefit from their fresh perspective on our current programs.”
The inaugural Catalyst Advocacy Scholars Summit will be held January 5 – 9, 2026, in Coral Gables, Fla.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull (858) 717-2310 david.schull@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.